63918 Federal Register / Vol. 79, No. 207 / Monday, October 27, 2014 / Notices 

email of new filings and issuances 

related to this or other pending projects. 

For assistance, contact FERC Online 

Support. 

Dated: October 21, 2014. 

Kimberly D. Bose, 

Secretary. 

[FR Doc. 2014–25544 Filed 10–24–14; 8:45 am] 

BILLING CODE 6717–01–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[FRL 9918–47–Region 2] 

Proposed CERCLA Section 122(h) Cost 

Recovery Settlement for the Hooker 

Chemical/Ruco Polymer Superfund 

Site, Located in Hicksville, Town of 

Oyster Bay, Nassau County, New York 

AGENCY: Environmental Protection 

Agency. 

ACTION: Notice; request for public 

comment. 

SUMMARY: In accordance with Section 

122(i) of the Comprehensive 

Environmental Response, 

Compensation, and Liability Act of 

1980, as amended (‘‘CERCLA’’), notice 

is hereby given by the U.S. 

Environmental Protection Agency 

(‘‘EPA’’), Region II, of a proposed cost 

recovery settlement agreement pursuant 

to Section 122(h) of CERCLA, with 

Occidental Chemical Corporation 

(‘‘Settling Party’’) for the Hooker 

Chemical/Ruco Polymer Superfund Site 

(the ‘‘Site’’), located in Hicksville, Town 

of Oyster Bay, Nassau County, New 

York. The Settling Party agrees to pay 

EPA $722,250 in reimbursement of past 

response costs related to EPA oversight 

of response actions performed by the 

Settling Party at the Site. 

The settlement includes a covenant by 

EPA not to sue or to take administrative 

action against the Settling party 

pursuant to Section 107(a) of CERCLA, 

with regard to the past response costs 

and future response costs as defined in 

the settlement agreement. For thirty (30) 

days following the date of publication of 

this notice, EPA will receive written 

comments relating to the settlement. 

EPA will consider all comments 

received and may modify or withdraw 

its consent to the settlement if 

comments received disclose facts or 

considerations that indicate that the 

proposed settlement is inappropriate, 

improper or inadequate. EPA’s response 

to any comments received will be 

available for public inspection at EPA 

Region II, 290 Broadway, New York, 

New York 10007–1866. 

DATES: Comments must be submitted on 

or before November 26, 2014. 

ADDRESSES: The proposed settlement is 

available for public inspection at EPA 

Region II offices at 290 Broadway, New 

York, New York 10007–1866. Comments 

should reference the Hooker Chemical/ 

Ruco Polymer Superfund Site, located 

in Hicksville, Town of Oyster Bay, 

Nassau County, New York, Index No. 

CERCLA–02–2014–2017. To request a 

copy of the proposed settlement 

agreement, please contact the EPA 

employee identified below. 

FOR FURTHER INFORMATION CONTACT: 

Argie Cirillo, Assistant Regional 

Counsel, New York/Caribbean 

Superfund Branch, Office of Regional 

Counsel, U.S. Environmental Protection 

Agency, 290 Broadway—17th Floor, 

New York, New York 10007–1866. 

Telephone: 212–637–3178. 

Dated: October 14, 2014. 

Walter Mugdan, 

Director, Emergency and Remedial Response 

Division, U.S. Environmental Protection 

Agency, Region 2. 

[FR Doc. 2014–25477 Filed 10–24–14; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The applications will also be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than November 21, 

2014. 

A. Federal Reserve Bank of Cleveland 

(Nadine Wallman, Vice President) 1455 

East Sixth Street, Cleveland, Ohio 

44101–2566: 

1. Citizens National Corporation, 

Paintsville, Kentucky; to acquire 100 

percent of the voting shares of Peoples 

Security Bancorp, Inc., and thereby 

indirectly acquire voting shares of 

Peoples Security Bank of Louisa, both in 

Louisa, Kentucky. 

B. Federal Reserve Bank of San 

Francisco (Gerald C. Tsai, Director, 

Applications and Enforcement) 101 

Market Street, San Francisco, California 

94105–1579: 

1. FNB Bancorp, South San Francisco, 

California; to acquire 100 percent of the 

voting shares of Valley Community 

Bank, Pleasanton, California. 

Board of Governors of the Federal Reserve 

System, October 22, 2014. 

Michael J. Lewandowski, 

Associate Secretary of the Board. 

[FR Doc. 2014–25474 Filed 10–24–14; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Notice of Interest Rate on Overdue 

Debts 

Section 30.18 of the Department of 

Health and Human Services’ claims 

collection regulations (45 CFR part 30) 

provides that the Secretary shall charge 

an annual rate of interest, which is 

determined and fixed by the Secretary 

of the Treasury after considering private 

consumer rates of interest on the date 

that the Department of Health and 

Human Services becomes entitled to 

recovery. The rate cannot be lower than 

the Department of Treasury’s current 

value of funds rate or the applicable rate 

determined from the ‘‘Schedule of 

Certified Interest Rates with Range of 

Maturities’’ unless the Secretary waives 

interest in whole or part, or a different 

rate is prescribed by statute, contract, or 

repayment agreement. The Secretary of 

the Treasury may revise this rate 

quarterly. The Department of Health and 

Human Services publishes this rate in 

the Federal Register. 

The current rate of 103⁄4%, as fixed by 

the Secretary of the Treasury, is certified 

for the quarter ended September 30, 

2014. This rate is based on the Interest 


tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 207 / Monday, October 27, 2014 / Notices 63919 

Rates for Specific Legislation, ‘‘National 

Health Services Corps Scholarship 

Program (42 U.S.C. 250(B)(1)(A))’’ and 

‘‘National Research Service Award 

Program (42 U.S.C. 288(c)(4)(B)).’’ This 

interest rate will be applied to overdue 

debt until the Department of Health and 

Human Services publishes a revision. 

Dated: October 16, 2014. 

David C. Horn, 

Director, Office of Financial Policy and 

Reporting. 

[FR Doc. 2014–25443 Filed 10–24–14; 8:45 am] 

BILLING CODE 4150–04–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–1635–N] 

Medicare, Medicaid, and Children’s 

Health Insurance Programs; Advisory 

Panel on Clinical Diagnostic 

Laboratory Tests and Request for 

Nominations 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

establishment of an Advisory Panel on 

Clinical Diagnostic Laboratory Tests (the 

Panel) and requests nominations for 

individuals to serve on the Panel. 

DATES: Nominations will be considered 

if we receive them at the appropriate 

address, provided in the ADDRESSES

section of this notice, no later than 5 

p.m., e.d.t. on November 26, 2014. 

ADDRESSES: Mail or deliver written 

nominations for membership to the 

following address: Glenn C. McGuirk, 

Designated Federal Official, Center for 

Medicare, Division of Ambulatory 

Services, CMS, 7500 Security 

Boulevard, Mail Stop C4–01–26, 

Baltimore, MD 21244, or email to 

Glenn.McGuirk@cms.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Glenn C. McGuirk, 410–786–5723, email 

Glenn.McGuirk@cms.hhs.gov, or visit 

the Web site http://www.cms.gov/

Medicare/Medicare-Fee-for-ServicePayment/ClinicalLabFeeSched/

index.html?redirect=/

ClinicalLabFeeSched/. 

Press inquiries are handled through 

the CMS Press Office at (202) 690–6145. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Advisory Panel on Clinical 

Diagnostic Laboratory Tests is 

authorized by section 1834A(f)(1) of the 

Social Security Act (the Act) (42 U.S.C. 

1395m–1), as established by section 216 

of the Protecting Access to Medicare Act 

of 2014 (PAMA) (Pub L. 113–93, 

enacted April 1, 2014), and is subject to 

the Federal Advisory Committee Act 

(FACA), as amended (5 U.S.C. 

Appendix 2), which sets forth standards 

for the formation and use of advisory 

panels. 

II. Provisions of This Notice 

A. Objectives and Scope of the Panel 

Section 1834A of the Act requires the 

establishment of new Medicare payment 

rates for clinical diagnostic laboratory 

tests furnished on or after January 1, 

2017, based on private payor rates, and 

establishes processes for determining 

initial payments for new clinical 

diagnostic laboratory tests (including 

advanced diagnostic laboratory tests). 

As set forth in section 1834A(f)(1) of the 

Act, the Secretary of Health and Human 

Services (the Secretary) will consult 

with an expert outside advisory panel, 

to be established by the Secretary not 

later than July 1, 2015, composed of an 

appropriate selection of individuals 

with expertise in issues related to 

clinical diagnostic laboratory tests. Such 

individuals may include representatives 

of clinical laboratories, molecular 

pathologists, clinical laboratory 

researchers, and individuals with 

expertise in clinical laboratory science 

or economics of clinical laboratory 

services. The Panel will provide input 

to the Secretary and the Administrator 

of the Centers for Medicare & Medicaid 

Services (CMS) on the following: 

• The establishment of payment rates 

under section 1834A of the Act for new 

clinical diagnostic laboratory tests, 

including whether to use crosswalking 

or gapfilling processes to determine 

payment for a specific new test; and 

• The factors used in determining 

coverage and payment processes for 

new clinical diagnostic laboratory tests. 

In addition, the Panel will provide 

recommendations to the Secretary and 

the Administrator of CMS under section 

1834A of the Act. 

B. Description of Duties 

The Panel will provide input and 

recommendations on the following 

issues: 

• Calculation of weighted median for 

laboratory services using private payor 

rates. 

• Phase-in of reductions from private 

payor rate implementation. 

• Application of market rates. 

• Evaluation and designation of tests 

as advanced diagnostic laboratory tests. 

• Whether to use crosswalking or 

gapfilling to determine payment for a 

specific new test. 

• The factors used in determining 

coverage or payment processes for new 

clinical diagnostic laboratory tests. 

The subject matter before the Panel 

will be limited to these and related 

topics. Unrelated topics will not be 

subjects for discussion. Unrelated topics 

will include, but are not limited to, 

definition of an applicable laboratory for 

purposes of reporting private payor 

data, definition of a data collection 

period, treatment of discounts, reporting 

of more than one payment rate for the 

same payor, certification of data, 

definition of a private payor, civil 

monetary penalties for noncompliance 

with reporting requirements, and 

generally, Medicare conditions of 

payment for clinical diagnostic 

laboratory tests. 

Panel meetings will be held up to 4 

times a year. The Panel will consist of 

up to 15 individuals and a Chair. The 

Panel Chair will be a federal official 

who is designated by the Secretary or 

the Administrator of CMS. The Panel 

Chair will facilitate meetings and the 

Designated Federal Officer (DFO) or 

designee must be present at all 

meetings. Meetings will be open to the 

public except as determined otherwise 

by the Secretary or other official to 

whom the authority has been delegated 

in accordance with the Government in 

the Sunshine Act of 1976 (5 U.S.C. 

552b(c)) and FACA. Notice of all 

meetings will be published in the 

Federal Register as required by 

applicable laws and Departmental 

regulations. Meetings will be conducted, 

and records of the proceedings kept, as 

required by applicable laws and 

departmental regulations. 

To conduct the business of the Panel, 

a quorum is required. A quorum exists 

when a majority of currently appointed 

members is present at full Panel or 

subcommittee meetings or is 

participating in conference calls. 

Unless renewed by appropriate action 

prior to expiration, the Panel will 

terminate 2 years from the filing date of 

its charter. 

C. Request for Nominations 

We are requesting nominations for 

members to serve on the Panel. As noted 

previously, the Panel will consist of up 

to 15 individuals with expertise in 

issues related to clinical diagnostic 

laboratory tests, which may include 

representatives of clinical laboratories, 

molecular pathologists, clinical 

laboratory researchers, and individuals 

with expertise in clinical laboratory 

science or economics of clinical 


tkelley on DSK3SPTVN1PROD with NOTICES